Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although meta-analyses have shown that placebo responses are large in Major Depressive Disorder (MDD) trials; the placebo response of devices such as repetitive transcranial magnetic stimulation (rTMS) has not been systematically assessed. We proposed to assess placebo responses in two categories of MDD trials: pharmacological (antidepressant drugs) and non-pharmacological (device- rTMS) trials. METHODOLOGY/PRINCIPAL FINDINGS: We performed a systematic review and meta-analysis of the literature from April 2002 to April 2008, searching MEDLINE, Cochrane, Scielo and CRISP electronic databases and reference lists from retrieved studies and conference abstracts. We used the keywords placebo and depression and escitalopram for pharmacological studies; and transcranial magnetic stimulation and depression and sham for non-pharmacological studies. All randomized, double-blinded, placebo-controlled, parallel articles on major depressive disorder were included. Forty-one studies met our inclusion criteria - 29 in the rTMS arm and 12 in the escitalopram arm. We extracted the mean and standard values of depression scores in the placebo group of each study. Then, we calculated the pooled effect size for escitalopram and rTMS arm separately, using Cohen's d as the measure of effect size. We found that placebo response are large for both escitalopram (Cohen's d - random-effects model - 1.48; 95%C.I. 1.26 to 1.6) and rTMS studies (0.82; 95%C.I. 0.63 to 1). Exploratory analyses show that sham response is associated with refractoriness and with the use of rTMS as an add-on therapy, but not with age, gender and sham method utilized. CONCLUSIONS/SIGNIFICANCE: We confirmed that placebo response in MDD is large regardless of the intervention and is associated with depression refractoriness and treatment combination (add-on rTMS studies). The magnitude of the placebo response seems to be related with study population and study design rather than the intervention itself.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“methodological issues, including aspects of study design and conduct (i.e., issues with identifying appropriate patients, large multi-site trials, multiple raters) that have been previously proposed as possible reasons for negative clinical trials in MDD”
From A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD (2015) · cites this paper as Brunoni et al., 2009
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, to our knowledge, our review provides the first comprehensive insight into the control group response in non-pharmacological interventions in depression.”
From Challenges establishing the efficacy of exercise as an antidepressant treatment: a systematic review and meta-analysis of control group responses in exercise randomised controlled trials (2016) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The authors [19] found a similar increased control group improvement (SMD=-0.8) to ourselves”
The cited source says what the claim attributes to it.
In the citing paper
“response rates to placebo can be high in clinical trials of MDD (Brunoni et al, 2009;Walsh et al, 2002)”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Brunoni et al, 2009
In the citing paper
“A large placebo response has also been reported in non-pharmacological interventions for depression, with a recent meta-analysis demonstrating an effect size of 0.82 (95% CI 0.63 to 1) for control group responses in trials of repetitive transcranial magnetic stimulation [19].”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“We also performed sensitivity analysis, cumulative regression and assessed publication bias using Beggmodified funnel plot and Egger test [24] for each analysis.”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“Unsuccessful blinding biases the results as expectation effects and intervention confidence will be lost [45,46,47,48], therefore diminishing placebo response.”
BackgroundMoher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560 · cited 1×
“Unsuccessful blinding biases the results as expectation effects and intervention confidence will be lost [45,46,47,48], therefore diminishing placebo response.”
BackgroundKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442 · cited 4×
“The main finding of our study is that both placebo interventions are associated with a large effect size in major depressive disorder, which is in line with previous studies: Walsh et al. [1] reviewed 75 depression trials and concluded that placebo response is substantial and increasing over years; Stein et al. [35] i…”
BackgroundInfluentialSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 1×
“However, our study is in line with previous meta-analyses that showed similar placebo responses in major depression studies [1,52], assessed a significant number (1714) of patients and included unpublished studies; therefore this hypothesis is less likely.”
ResultPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 4×
“7% [1] and that drug-placebo differences might be relatively small in patients with MDD due to the large placebo response [2].”
BackgroundResultInfluentialSham device v inert pill: randomised controlled trial of two placebo treatments
Kaptchuk, T. J., Stason, W. B., Davis, R. B., Legedza, A. R. T., Schnyer, R. N., Kerr, C. E., Stone, D. A., Nam, B. H., Kirsch, I., & Goldman, R. H. (2006) · BMJ · doi:10.1136/bmj.38726.603310.55 · Cited by 532 · cited 2×
“inert pill trial [37] and in a metaanalysis comparing subcutaneous placebo with oral placebo from acute migraine [38].”
BackgroundSelf-citationDo medical devices have enhanced placebo effects?
Kaptchuk, T. J., Goldman, P., Stone, D. A., & Stason, W. B. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00206-7 · Cited by 463 · cited 2×
“placebo response than placebo pills [8,36].”
BackgroundSelf-citationFitzgerald, P. B., Brown, T. L., Marston, N. A. U., Daskalakis, Z. J., de Castella, A., & Kulkarni, J. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.1002 · Cited by 458 · cited 1×
“For rTMS studies that used MADRS scores as the primary outcome, we used the values of HDRS scores reported in secondary outcomes when this was possible [26,28,29,30,31]; in four studies this was not possible [20,32,33,34] and therefore we imputed missing HDRS scores regressing for other variables.”
MethodReporting methods of blinding in randomized trials assessing nonpharmacological treatments
Boutron, I., Guittet, L., Estellat, C., Moher, D., Hróbjartsson, A., & Ravaud, P. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040061 · Cited by 389 · cited 1×
“(2) Study designs are different: although escitalopram and rTMS trials present comparable quality, they mainly differ in blinding quality, as adequate blinding is more difficult to obtain in non-pharmacological interventions [44].”
BackgroundSchutter, D. J. L. G. (2009) · Psychological Medicine · doi:10.1017/s0033291708003462 · Cited by 371 · cited 1×
“Several meta-analyses of rTMS clinical trials have been performed in the past ten years, initially showing negative or poor results [3,4]; although two recent studies have demonstrated a greater efficacy of the method [5,6].”
ResultFitzgerald, P. B., Benitez, J., de Castella, A., Daskalakis, Z. J., Brown, T. L., & Kulkarni, J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.88 · Cited by 363 · cited 1×
“For rTMS studies that used MADRS scores as the primary outcome, we used the values of HDRS scores reported in secondary outcomes when this was possible [26,28,29,30,31]; in four studies this was not possible [20,32,33,34] and therefore we imputed missing HDRS scores regressing for other variables.”
MethodFixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350 · cited 1×
“Many escitalopram studies did not report SD final scores – in these cases, we calculated SD from standard error (SE) at end-of-treatment or from SD or SE difference changes when possible [11,12].”
MethodLisanby, S. H., Husain, M. M., Rosenquist, P. B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L. B., Aaronson, S., Daskalakis, Z. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.118 · Cited by 333
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Lam, R. W., Chan, P., Wilkins-Ho, M., & Yatham, L. N. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300909 · Cited by 297 · cited 10×
“Our results show that sham-response is smaller in trials that rTMS is not used as add-on therapy (0.56 vs. 1.24), suggesting that such device might not be associated with a large placebo effect, a finding that was also observed in meta-analyses of Parkinson’s disease [51] and of refractory MDD [41].”
BackgroundResultInfluentialde Craen, A. J. M., Tijssen, J. G. P., de Gans, J., & Kleijnen, J. (2000) · Journal of Neurology · doi:10.1007/s004150050560 · Cited by 292
Martin, J. L. R., Barbanoj, M. J., Schlaepfer, T. E., Thompson, E., Pérez, V., & Kulisevsky, J. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.480 · Cited by 290 · cited 2×
“, with comparable sample sizes, diagnostic definitions, rating methods and quality of studies) and also because a meta-analysis performed in 2003 [3] stated that rTMS trials up to 2002 had been of low quality.”
ResultLoo, C. K., Taylor, J. L., Gandevia, S. C., McDarmont, B. N., Mitchell, P. B., & Sachdev, P. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00285-1 · Cited by 283 · cited 1×
“Clinical implications Because we addressed the influence of several variables in shamresponse, our results have some implications for future rTMS trial designs, such as: (1) sham device method is not associated with placebo response; therefore this factor seems less relevant than currently considered by the researcher…”
ResultGross, M., Nakamura, L., Pascual‐Leone, A., & Fregni, F. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01049.x · Cited by 279 · cited 1×
“Several meta-analyses of rTMS clinical trials have been performed in the past ten years, initially showing negative or poor results [3,4]; although two recent studies have demonstrated a greater efficacy of the method [5,6].”
ResultSelf-citationFregni, F. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.069849 · Cited by 267 · cited 1×
“24), suggesting that such device might not be associated with a large placebo effect, a finding that was also observed in meta-analyses of Parkinson’s disease [51] and of refractory MDD [41].”
ResultSelf-citationFergusson, D. (2004) · BMJ · doi:10.1136/bmj.37952.631667.ee · Cited by 264 · cited 1×
“Unsuccessful blinding biases the results as expectation effects and intervention confidence will be lost [45,46,47,48], therefore diminishing placebo response.”
BackgroundPredictors of antidepressant response in clinical trials of transcranial magnetic stimulation
Fregni, F., Marcolin, M. A., Myczkowski, M., Amiaz, R., Hasey, G., Rumi, D. O., Rosa, M., Rigonatti, S. P., Camprodon, J., Walpoth, M., et al. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006280 · Cited by 255 · cited 1×
“Clinical implications Because we addressed the influence of several variables in shamresponse, our results have some implications for future rTMS trial designs, such as: (1) sham device method is not associated with placebo response; therefore this factor seems less relevant than currently considered by the researcher…”
ResultSelf-citationLepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Papakostas, G. I., Shelton, R. C., Smith, J., & Fava, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0602 · Cited by 241 · cited 1×
“Along with these lines, low placebo responses were reported in a recent rTMS meta-analysis that addressed treatment-resistant patients [41] as well as two drug metaanalyses using lithium [42] and atypical antipsychotics [43].”
BackgroundWade, A., Michael Lemming, O., & Bang Hedegaard, K. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00001 · Cited by 231
Rumi, D. O., Gattaz, W. F., Rigonatti, S. P., Rosa, M. A., Fregni, F., Rosa, M. O., Mansur, C., Myczkowski, M. L., Moreno, R. A., & Marcolin, M. A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.029 · Cited by 218 · cited 1×
“Rumi [64] 24 38.”
Self-citationTreatment of Vascular Depression Using Repetitive Transcranial Magnetic Stimulation
Jorge, R. E., Moser, D. J., Acion, L., & Robinson, R. G. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.45 · Cited by 211 · cited 2×
“We contacted the corresponding authors in these cases [20,21,22,23].”
MethodWAGNER, K. D., JONAS, J., FINDLING, R. L., VENTURA, D., & SAIKALI, K. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000192250.38400.9e · Cited by 211 · cited 1×
“Wagner [74] 133 12.”
Couturier, J. L. (2005) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0514 · Cited by 207
Herwig, U., Fallgatter, A. J., Höppner, J., Eschweiler, G. W., Kron, M., Hajak, G., Padberg, F., Naderi-Heiden, A., Abler, B., Eichhammer, P., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.034371 · Cited by 194 · cited 1×
“For rTMS studies that used MADRS scores as the primary outcome, we used the values of HDRS scores reported in secondary outcomes when this was possible [26,28,29,30,31]; in four studies this was not possible [20,32,33,34] and therefore we imputed missing HDRS scores regressing for other variables.”
MethodJorge, R. E., Robinson, R. G., Tateno, A., Narushima, K., Acion, L., Moser, D., Arndt, S., & Chemerinski, E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.017 · Cited by 192 · cited 1×
“Jorge [60] 10 66.”
Mosimann, U. P., Schmitt, W., Greenberg, B. D., Kosel, M., Müri, R. M., Berkhoff, M., Hess, C. W., Fisch, H. U., & Schlaepfer, T. E. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2003.10.006 · Cited by 192
(2008) · Encyclopedia of Public Health · doi:10.1007/978-1-4020-5614-7_434 · Cited by 188
Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?
Trivedi, M. H., & Rush, J. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.63 · Cited by 175 · cited 1×
“[50] showed that response raters were different in depression controlled-trials regarding using or not a placebo run-in phase.”
MethodWhat are the main methodological problems in the estimation of placebo effects?
Hróbjartsson, A. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00496-6 · Cited by 171
Posternak, M. A., & Zimmerman, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028555 · Cited by 154 · cited 1×
“Furthermore, despite several metaanalyses assessing the placebo response of pharmacological trials in depression [1,2,9,10] placebo response of transcranial magnetic stimulation has not been sufficiently explored.”
BackgroundWalach, H. (2001) · The Journal of Alternative and Complementary Medicine · doi:10.1089/107555301300328070 · Cited by 148 · cited 1×
“placebo response than placebo pills [8,36].”
Herrmann, L. L., & Ebmeier, K. P. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1206 · Cited by 145 · cited 2×
“However, taking into account the heterogeneity of rTMS trials and the lack of precise predictors of outcome, Herrmann and Ebmeier [7] proposed that non-specific contextual effects - such as the use of a new and relatively unknown technological device and the running of trials in major universities and teaching hospita…”
BackgroundHöppner, J., Schulz, M., Irmisch, G., Mau, R., Schläfke, D., & Richter, J. (2003) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-003-0416-7 · Cited by 144
Escitalopram in the Treatment of Depressed Elderly Patients
Kasper, S. F., de Swart, H., & Andersen, H. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.884 · Cited by 140
A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression
LOO, C. K., MITCHELL, P. B., McFARQUHAR, T. F., MALHI, G. S., & SACHDEV, P. S. (2007) · Psychological Medicine · doi:10.1017/s0033291706009597 · Cited by 138
Herwig, U., Lampe, Y. M., Juengling, F. D., Wunderlich, A. P., Walter, H., Spitzer, M., & Schönfeldt‐Lecuona, C. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00042-6 · Cited by 136
Nierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167453 · Cited by 131 · cited 1×
“Two authors failed to provide the requested data [17,18]; in these cases we had to input SD posttreatment scores based on the mean of the available SD scores of other trials, a method suggested by The Cochrane Collaboration to be applied in such cases [19].”
MethodLOO, C. K., MITCHELL, P. B., CROKER, V. M., MALHI, G. S., WEN, W., GANDEVIA, S. C., & SACHDEV, P. S. (2003) · Psychological Medicine · doi:10.1017/s0033291702006839 · Cited by 130
Rossini, D., Lucca, A., Zanardi, R., Magri, L., & Smeraldi, E. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2005.06.008 · Cited by 127 · cited 1×
“We contacted the corresponding authors in these cases [20,21,22,23].”
MethodClayton, A. H., Croft, H. A., Horrigan, J. P., Wightman, D. S., Krishen, A., Richard, N. E., & Modell, J. G. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0507 · Cited by 126
Hausmann, A., Kemmler, G., Walpoth, M., Mechtcheriakov, S., Kramer-Reinstadler, K., Lechner, T., Walch, T., Deisenhammer, E., Köfler, M., Rupp, C. I., et al. (2004) · PubMed Central · Cited by 123
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121 · cited 3×
“We also received data from Forest Labs of two posters [15,16] and for an unpublished trial mentioned in another study [13].”
MethodStein, D. J., Baldwin, D. S., Dolberg, O. T., Despiegel, N., & Bandelow, B. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1111 · Cited by 120 · cited 1×
“[35] in a pooled analysis of five escitalopram trials showed that placebo response ranged from 31.”
BackgroundStern, W. M., Tormos, J. M., Press, D. Z., Pearlman, C., & Pascual-Leone, A. (2007) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.2007.19.2.179 · Cited by 117 · cited 1×
“Stern [69] 10 53.”
Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older
Bose, A., Li, D., & Gandhi, C. C. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181591c09 · Cited by 108 · cited 2×
“In two studies, SD had been only reported in graphs and we asked for data from Forest Research Institute [13,14].”
MethodBretlau, L., Lunde, M., Lindberg, L., Undén, M., Dissing, S., & Bech, P. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-993210 · Cited by 104 · cited 1×
“were treated as categorical variables. It should be underscored that we classified as “angled coil” studies that described the use of an active rTMS coil in a different angle or position when applied to the scalp; whereas “sham coil” included studies that used a non-active coil associated with a method to preserve bli…”
MethodHoltzheimer, P. E., Russo, J., Claypoole, K. H., Roy-Byrne, P., & Avery, D. H. (2004) · Depression and Anxiety · doi:10.1002/da.10147 · Cited by 104
Su, T.-P., Huang, C.-C., & Wei, I.-H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0718 · Cited by 102 · cited 1×
“Su [65] 10 42.”
Rossini, D., Magri, L., Lucca, A., Giordani, S., Smeraldi, E., & Zanardi, R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1212 · Cited by 102 · cited 1×
“Rossini (J Clin Psych) [63] 49 46.”
Mogg, A., Pluck, G., Eranti, S. V., Landau, S., Purvis, R., Brown, R. G., Curtis, V., Howard, R., Philpot, M., & McLoughlin, D. M. (2008) · Psychological Medicine · doi:10.1017/s0033291707001663 · Cited by 100 · cited 1×
“Mogg [71] 30 52 21 HDRS 21.”
Januel, D., Dumortier, G., Verdon, C.-M., Stamatiadis, L., Saba, G., Cabaret, W., Benadhira, R., Rocamora, J.-F., Braha, S., Kalalou, K., et al. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.016 · Cited by 100 · cited 1×
“Januel [66] 16 37.”
García-Toro, M., Salvá, J., Daumal, J., Andres, J., Romera, M., Lafau, O., Echevarría, M., Mestre, M., Bosch, C., Collado, C. T., et al. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.08.005 · Cited by 99
Boutros, N. N., Gueorguieva, R. V., Hoffman, R. E., Oren, D. A., Feingold, A., & Berman, R. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00267-6 · Cited by 86 · cited 1×
“Boutros [57] 9 49.”
Koerselman, F., Laman, D. M., van Duijn, H., van Duijn, M. A. J., & Willems, M. A. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1005 · Cited by 78 · cited 1×
“Koerselman [58] 26 52 17 HDRS 25.”
Transcranial Magnetic Stimulation for Depression
Mitchell, P. B., & Loo, C. K. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01816.x · Cited by 77
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods, S. W., Gueorguieva, R. V., Baker, C. B., & Makuch, R. W. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.961 · Cited by 72 · cited 1×
“[49] showed that, in schizophrenia controlled-trials, improvement was larger in trials having no placebo arm; and Trivedi et al.”
BackgroundBortolomasi, M., Minelli, A., Fuggetta, G., Perini, M., Comencini, S., Fiaschi, A., & Manganotti, P. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2006.04.010 · Cited by 68 · cited 1×
“Bortolomasi [70] 7 55.”
Adjunctive fast repetitive transcranial magnetic stimulation in depression
Anderson, I. M., Delvai, N. A., Ashim, B., Ashim, S., Lewin, C., Singh, V., Sturman, D., & Strickland, P. L. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028019 · Cited by 58 · cited 1×
“For rTMS studies that used MADRS scores as the primary outcome, we used the values of HDRS scores reported in secondary outcomes when this was possible [26,28,29,30,31]; in four studies this was not possible [20,32,33,34] and therefore we imputed missing HDRS scores regressing for other variables.”
MethodBaethge, C., Smolka, M. N., Gruschka, P., Berghöfer, A., Schlattmann, P., Bauer, M., Altshuler, L. L., Grof, P., & Müller-Oerlinghausen, B. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.02057.x · Cited by 58 · cited 1×
“Along with these lines, low placebo responses were reported in a recent rTMS meta-analysis that addressed treatment-resistant patients [41] as well as two drug metaanalyses using lithium [42] and atypical antipsychotics [43].”
BackgroundAcceleration and augmentation strategies for treating bipolar depression
Altshuler, L. L., Frye, M. A., & Gitlin, M. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00087-8 · Cited by 53 · cited 1×
“, patients from sham group were actually starting an active drug treatment -in fact, this is the same concept of an ‘‘accelerating’’ study [27].”
BackgroundMeta-Analysis of Placebo Rates in Major Depressive Disorder Trials
Stolk, P., Berg, M. J. T., Hemels, M. E., & Einarson, T. R. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d172 · Cited by 52 · cited 1×
“Furthermore, despite several metaanalyses assessing the placebo response of pharmacological trials in depression [1,2,9,10] placebo response of transcranial magnetic stimulation has not been sufficiently explored.”
BackgroundRepetitive transcranial magnetic stimulation does not potentiate antidepressant treatment
Poulet, E., Brunelin, J., Boeuve, C., Lerond, J., D’Amato, T., Dalery, J., & Saoud, M. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.021 · Cited by 47 · cited 2×
“We contacted the corresponding authors in these cases [20,21,22,23].”
MethodSchwartz, N. A., Turturro, M. A., Istvan, D. J., & Larkin, G. L. (2000) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2000.tb02061.x · Cited by 39 · cited 1×
“Our finding does however agree with a smaller acute care study that found no difference between parenteral medication and oral medication [39].”
ResultO'Reardon, J. P., Cristancho, P., Pilania, P., Bapatla, K. B., Chuai, S., & Peshek, A. D. (2007) · Depression and Anxiety · doi:10.1002/da.20261 · Cited by 38
Cited by
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
Brunoni, A. R., Valiengo, L., Baccaro, A., Zanão, T. A., de Oliveira, J. F., Goulart, A., Boggio, P. S., Lotufo, P. A., Benseñor, I. M., & Fregni, F. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.32 · Cited by 601
Self-citationAnimal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
“Due to high placebo response rates (Brunoni et al. 2009) and side effect concerns, monoamine-based agents still constitute a significant proportion of “new” antidepressants being tested in clinical trials (Mathew et al. 2008).”
BackgroundSmith, C. A., Hay, P. P., & MacPherson, H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004046.pub3 · Cited by 323
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
Richard, I. H., McDermott, M. P., Kurlan, R., Lyness, J. M., Como, P. G., Pearson, N., Factor, S. A., Juncos, J., Serrano Ramos, C., Brodsky, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182516244 · Cited by 338
Metadata
- Authors
- Brunoni, A. R., Lopes, M., Kaptchuk, T. J., & Fregni, F.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Corresponding author
- Fregni, Felipe
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-18
- Volume
- 4
- Issue
- 3
- Pages
- e4824
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2653635
- OpenAlex
- W2057880023
- Cited by
- 173
- References
- 74
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 13 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 6 · 2016: 6 · 2015: 15 · 2014: 10 · 2013: 16 · 2012: 13
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Center for Complementary and Integrative Health (K24AT004095)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- placebo response, major depressive disorder, repetitive transcranial magnetic stimulation, escitalopram, antidepressants, treatment-resistant depression, adjunctive therapy
- MeSH terms
- Major Depressive Disorder, Double-Blind Method, Humans, Placebos, Citalopram, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.